Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Incyte

INDIANAPOLIS, April 8, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care (SoC) versus placebo plus SoC. The trial did not meet statistical significance on the primary endpoint, which was defined as a difference in the proportion of participants progressing to the first occurrence of non-invasive ventilation including high flow oxygen or invasive mechanical ventilation including extracorporeal membrane oxygenation (ECMO) or death by Day 28.

Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients

The FDA extends the review period of Lilly (LLY)/Incyte's (INCY) label expansion application for Olumiant in atopic dermatitis by three months.

Lilly's (LLY) Olumiant Dermatitis sNDA Review Gets Delayed

INDIANAPOLIS, April 6, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for baricitinib for the treatment of adults with moderate to severe atopic dermatitis (AD). The FDA extended the action date to allow time to review additional data analyses submitted by Lilly in response to recent information requests from the FDA.

Lilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis

INDIANAPOLIS, April 6, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2021 financial results on Tuesday, April 27, 2021. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.

Lilly Confirms Date and Conference Call for First-Quarter 2021 Financial Results Announcement

INDIANAPOLIS, April 1, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will host a webcast for the investment community, media and the general public on May 4, 2021 to provide an overview of the company's strong commitment to sustainability efforts in the areas of Environmental, Social and Governance (ESG). The webcast will include remarks from David A.

Lilly to Host Sustainability Webcast to Provide Overview of Environmental, Social and Governance (ESG) Efforts

RIDGEFIELD, Conn. and INDIANAPOLIS, March 31, 2021 /PRNewswire/ -- Approximately 9 in 10 specialists agree that people with type 2 diabetes whose healthcare professionals (HCPs) collaborate tend to have better outcomes than those whose HCPs do not, while the top barrier to more collaboration among specialists is lack of time.

Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care

Pfizer

It looks like an uphill battle for tanezumab.

Could Pfizer's and Lilly's Long-Awaited Osteoarthritis Drug Flop?

A 17-year veteran of the company alleges she was bullied by a supervisor.

Eli Lilly Is Facing A Lawsuit Alleging A ‘Sexually Hostile Work Environment' From A Former Lobbyist

Eli Lilly (LLY), Vir Biotechnology and Glaxo are developing a combination of their respective monoclonal antibodies as a potential treatment for mild-to-moderate COVID-19 patients.

Lilly/Vir's Cocktail COVID-19 Therapy Meets Study Endpoint

Vir Biotechnology

Eli Lilly And Co (NYSE: LLY), Vir Biotechnology Inc (NASDAQ: VIR), and GlaxoSmithKline plc (NYSE: GSK) have announced topline data from the expanded Phase 2 BLAZE-4 trial evaluating bamlanivimab co-administered with VIR-7831 in low-risk adult patients with mild to moderate COVID-19. Results showed that bamlanivimab 700 mg co-administered with VIR-7831 500 mg demonstrated a 70% relative reduction in persistently high viral load at day seven compared to placebo, meeting the primary endpoint.

Eli Lilly-Vir Bamlanivimab-VIR-7831 Combo Reduces Viral Load By 70% In Low-Risk COVID-19 Patients

GlaxoSmithKline

Eli Lilly & Co. , Vir Biotechnology Inc. and GlaxoSmithKline PLC on Monday reported positive data from a Phase 2 trial evaluating the combination of two monoclonal antibodies in treating low-risk adult COVID-19 patients. The trial found combining Lilly's bamlanivimab with Vir's VIR-7831 showed a 70% reduction in persistently high viral load at day 7 compared to placebo.

Eli Lilly, Vir and Glaxo say Phase 2 trial combining antibodies reduced viral load by 70% at day 7

INDIANAPOLIS and SAN FRANCISCO and LONDON, March 29, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced topline data from the expanded Phase 2 BLAZE-4 trial studying low-risk adult patients with mild to moderate COVID-19. Results showed that investigational bamlanivimab (LY-CoV555) 700 mg co-administered with VIR-7831 (also known as GSK4182136) 500 mg demonstrated a 70 percent (p 5.27; cycle threshold value < 27.5) at day 7 compared to placebo, meeting the primary endpoint.

Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19

It's a big-name pharma with a storied history, but Eli Lilly still has plenty of room left to run.

This Stalwart's Growth Story Isn't Over Yet

Automatic Data Processing

General Dynamics

Intel

Johnson & Johnson

Medtronic

Merck

NIKE

Procter & Gamble

Visa

This monthly series ranks a selection of dividend growth stocks in Dividend Radar, presenting the 10 top-ranked stocks for consideration. To rank stocks, I use DVK Quality Snapshots to get quality scores and sort them in descending order, breaking ties with additional metrics.

10 Dividend Growth Stocks For March 2021

A former top lobbyist for pharmaceutical giant Eli Lilly & Co accused a high-ranking executive and another senior manager of engaging in sexual discrimination, harassment and retaliation against women in its Washington D.C. office, according to a lawsuit filed Friday.

Exclusive: Ex-lobbyist sues Eli Lilly alleging sexual discrimination, harassment

AbbVie

Amgen

Bristol-Myers

Gilead Sciences

Sanofi

Pharmaceutical stocks with stable, substantial dividends can hold their own in almost any environment, making them ideal for long-term income investors.

7 Big Pharmaceutical Stocks for Bigger Income

An expert panel of the U.S. Food and Drug Administration has rejected Pfizer Inc. (NYSE: PFE) and Eli Lilly and Company's (NYSE: LLY) application to approve their experimental drug for the treatment of osteoarthritis pain, citing safety risks and an inadequate plan to manage them. What Happened: The FDA's Joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee voted 19-1 that the drug Tanezumab's risks outweigh its benefits for patients with moderate-to-severe osteoarthritis pain, Pfizer and Eli Lilly said in a statement Thursday.

Pfizer And Eli Lilly's Osteoarthritis Drug Rejected By FDA Panel As Too Risky

Pfizer Inc. and Eli Lilly and Co. said Thursday that a joint advisory committee of the U.S. Food and Drug Administration has voted against their investigational tanezumab drug for the treatment of certain types of arthritis in adults when use of other drugs aren't possible. "While we are disappointed with today's outcome, we continue to believe that tanezumab has a positive benefit-risk profile for patients with moderate-to-severe osteoarthritis pain for whom current treatments are ineffective or not appropriate," Ken Verburg, tanezumab development team leader at Pfizer, said in a statement.

Pfizer, Eli Lilly say experimental arthritis drug tanezumab hits FDA snag

NEW YORK & INDIANAPOLIS--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced the outcome of the U.S. Food and Drug Administration (FDA) Joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee on tanezumab. There was a single voting question focused on whether the proposed risk evaluation and mitigation strategy (REMS) for tanezumab will ensure its benefits outweigh its risks, and the Committee voted 1 in favor and 19 aga

Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain

Ahead of an advisory committee meeting scheduled for later this week, the FDA released its in-depth review of Pfizer Inc (NYSE: PFE) and Eli Lilly And Co's (NYSE: LLY) tanezumab, an anti-NGF osteoarthritis drug. What Happened: Potential FDA approval for tanezumab still looked rocky as the regulator casts doubt over its safety.

Pfizer/Eli Lilly's Tanezumab Safety Profile Fails To Impress FDA Even After 15 Years Of Development Across 41 Trials

The stock price of Eli Lilly & Company has seen a 10% drop over the last five trading days, after the company announced mixed results from clinical trials of Donanemab, a drug for the treatment of Alzheimer's disease. While the drug met the primary endpoint, it failed to meet a more important.

Can Eli Lilly Stock Rebound After A 10% Drop Over Alzheimer's Drug?

Regeneron Pharmaceuticals

The FDA updated its fact sheets on the monoclonal antibody (mAb) treatments for COVID-19 from Eli Lilly And Co (NYSE: LLY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN), highlighting additional data on the vulnerability of the emerging COVID-19 variants to each of the mAb therapies. “Some variants can cause resistance to one or more of the mAb therapies authorized to treat COVID-19,” FDA said.

FDA Updates Fact Sheets For Eli Lilly, Regeneron's COVID-19 Antibody Therapies Under Emergency Use

In a webinar with the American Medical Association, the FDA acting commissioner Janet Woodcock said that the U.S. government is not distributing Eli Lilly And Co's (NYSE: LLY) bamlanivimab in California, Arizona, and Nevada amid prevalent COVID-19 virus variant. A Lilly spokesperson, when spoke to Endpoints News, said, “We recognize the U.S. government has made the decision to no longer allow direct ordering of bamlanivimab alone in California, Arizona, and Nevada due to concerns about the prevalence of the ‘California' variant, with the specific L452R substitution found in B.1.429/B.1.427 lineages.

Amid Variant Concern, US Government Stops Distribution Of Eli Lilly's Bamlanivimab In Three States

Shares of Eli Lilly & Co. were up 0.2% in premarket trading on Thursday after the drug maker confirmed that the U.S. government is no longer allowing its monoclonal antibody bamlanivimab to be ordered in Arizona, California, and Nevada over concerns about its effectiveness against the so-called "California" variant. Lilly first received emergency authorization for bamlanivimab in November, and it later received authorization for a combination of bamlanivimab and etesevimab.

Lilly says its monoclonal antibody is no longer being ordered in 3 states due to variant concerns

Lilly's (LLY) mirikizumab meets primary endpoint and key secondary endpoints in phase III ulcerative colitis study.

News for Eli Lilly Stock (LLY)